Hi-8 MEL: Phase I/II data

In a dose-escalation, U.K. and German Phase I/II trial in 41 patients with HLA-A2-positive, Stage III/IV non-resectable melanoma, Hi-8 MEL was well tolerated and met the clinical endpoints. Of the 8 p...